There are 304 resources available
The microbiome and immunotherapy in NSCLC
Presenter: Lisa Derosa
Session: The future of immunotherapy in thoracic oncology
Resources:
Slides
Webcast
Q&A and discussion
Presenter: All Speakers
Session: The future of immunotherapy in thoracic oncology
Resources:
Webcast
Q&A and discussion
Presenter: All Speakers
Session: Anti-cancer pathogen-derived therapies
Resources:
Webcast
Role of androgen receptor activity in T cell inhibition and potential for therapeutic intervention
Presenter: Amy Moran
Session: Leveraging insights from basic cancer immunology for translation
Resources:
Slides
Webcast
118O - Definitive results for NSCLC and Bladder cancer cohorts in the phase 2a trial of visugromab (CTL-002) in advanced/metastatic anti-PD/PD-L1 relapsed/refractory solid tumors (GDFATHER-trial)
Presenter: Ignacio Melero
Session: Proffered Paper session 1
Resources:
Abstract
Checkpoint blockade and CNS tumour microenvironment
Presenter: Bart Neyns
Session: The future of CNS tumors: Learning from failures and driven by biology
Resources:
Slides
Webcast
Understanding T cell locations and targetable reservoirs for therapeutic modulation
Presenter: Nikhil Joshi
Session: Leveraging insights from basic cancer immunology for translation
Resources:
Slides
Webcast
LBA2 - First-line (1L) durvalumab plus platinum-etoposide for patients with extensive-stage SCLC (ES-SCLC): Primary results from the Phase 3b LUMINANCE study
Presenter: Niels Reinmuth
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Immunology and immunotherapy of meningioma
Presenter: Christel Herold-Mende
Session: The future of CNS tumors: Learning from failures and driven by biology
Resources:
Slides
Webcast
LBA3 - Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in first-line metastatic (m) NSCLC: 5-year overall survival (OS) update from the POSEIDON study
Presenter: Solange Peters
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast